v3.26.3
SHAREHOLDERS' EQUITY
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 8: SHAREHOLDERS’ EQUITY

 

  a. Reverse share split:

 

At the Company’s extraordinary general meeting of shareholders held on January 6, 2026, the Company’s shareholders approved amendments to the Company’s Articles of Association to effect (i) a reverse share split of the Company’s ordinary shares within a range of 1-for-2 to 1-for-12, to be effective at the ratio and on a date to be determined by the Board of Directors, and (ii) an increase in the Company’s authorized share capital to up to 100,000,000 ordinary shares following implementation of the reverse share split. On January 30, 2026, the Finance Committee of the Board approved a one-for-twelve reverse share split of the Company’s ordinary shares, and on February 16, 2026 approved amendments to the Company’s Articles of Association to reflect the implementation of the reverse share split and the increase in authorized share capital.

 

On February 24, 2026, the Company effected the one-for-twelve reverse share split of its ordinary shares. As a result of the reverse share split, every twelve issued and outstanding ordinary shares were automatically combined and converted into one ordinary share. The number of the Company’s issued and outstanding ordinary shares was reduced from 18,339,098 pre-split shares to 1,528,207 post-split shares. Concurrently, the total authorized number of ordinary shares under the Company’s Articles of Association increased from 75,000,000 ordinary shares to 100,000,000 ordinary shares.

 

Appropriate adjustments were also made to all outstanding derivative securities of the Company, including warrants, pre-funded warrants and stock options, such that the number of ordinary shares underlying such securities and the applicable exercise prices were proportionately adjusted in accordance with their terms and the Company’s equity incentive plans.

 

No fractional shares were issued in connection with the reverse share split and fractional shares were rounded down to the nearest whole share.

 

  b. Share option plans:

 

As of September 30, 2026, and December 31, 2025, the Company had reserved 372,127 and 39,851 ordinary shares, respectively, for issuance to the Company’s and its affiliates’ respective employees, directors, officers, and consultants pursuant to equity awards granted under the Company’s 2025 Incentive Compensation Plan (the “2025 Plan”). The Company’s shareholders approved the 2025 Plan on August 1, 2025, and it became effective on the same date. Certain awards granted under the Company’s prior 2014 Incentive Compensation Plan (the “2014 Plan”) remain outstanding and continue to be governed by its terms.

 

RSUs have been granted to non-employee directors and employees under the 2025 Plan. An RSU award represents a right to receive the Company’s ordinary shares upon vesting.

 

Options to purchase ordinary shares have been granted to employees and non-employee directors under the Company’s equity incentive plans.

 

Any options or RSUs that are forfeited or canceled before expiration become available for future grants under the 2025 Plan, as applicable.

 

Equity awards granted under the Company’s equity incentive plans generally vest over four years, with certain awards granted to non-employee directors vesting quarterly over one year.

 

The fair value for options granted during the nine months ended September 30, 2026, was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions:

 

   

Nine Months Ended

September 30,

 
    2026     2025  
Expected volatility     95.1 %     102.5 %
Risk-free rate     4.1 %     4.1 %
Dividend yield     -       -  
Expected term (in years)     6.08       6.25  
Share price   $ 6.53     $ 1.04  

 

A summary of employee and non-employee share options activity during the nine months ended September 30, 2026, is as follows:

 

    Number    

Weighted

average

exercise

price

   

Weighted

average

remaining

contractual

life (years)

   

Aggregate

intrinsic

value (in

thousands)

 
Options outstanding as of December 31, 2025     52,450     $ 13.86       9.43     $ -  
Granted     212,692       6.53       -       -  
Exercised     -       -       -       -  
Forfeited     (198,025 )     10.67       -       -  
Options outstanding as of September 30, 2026     67,117     $ 9.75       8.16     $ 2.8  
                                 
Options exercisable as of September 30, 2026     13,060     $ 20.87       3.30     $ -  

 

The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. No options were exercised during the nine months ended September 30, 2026 and 2025.

 

A summary of employee and non-employee RSUs activity during the nine months ended September 30, 2026 is as follows:

 

   

Number of

shares

underlying

outstanding

RSUs

   

Weighted-

average

grant date

fair value

 
Unvested RSUs as of December 31, 2025     73,433     $ 15.30  
Granted     118,506       7.04  
Vested     (29,593 )     16.41  
Forfeited     (30,033 )     11.34  
Unvested RSUs as of September 30, 2026     132,313     $ 8.55  

 

The fair value of RSUs granted is determined based on the price of the Company’s ordinary shares on the date of grant. The weighted average grant date fair value of RSUs granted during the nine months ended September 30, 2026 and 2025, was $7.04 and $8.40, respectively.

 

As of September 30, 2026, there were $1.2 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company’s 2014 Plan and 2025 Plan. This cost is expected to be recognized over a period of approximately 2.5 years.

 

The number of options and RSUs outstanding as of September 30, 2026 is set forth below, with options separated by range of exercise price.

 

Range of exercise price    

Options and RSUs

outstanding as of

September 30, 2026

   

Weighted

average

remaining

contractual

life (years) (1)

   

Options outstanding and

exercisable as of

September 30, 2026

   

Weighted

average

remaining

contractual

life (years) (1)

 
  RSUs       132,313       -       -       -  
  Options:                                  
$ 6.53       39,994       9.49       -       -  
$ 8.6       18,750       8.87       4,687       8.87  
$ 14.70       8,333       0.17       8,333       0.17  
$ 2,257.5-$4,200       40       1.33       40       1.33  
            199,430       8.16       13,060       3.30  

 

  (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

 

  c. Share-based awards to non-employee consultants:

 

As of September 30, 2026, there are no outstanding options or RSUs held by non-employee consultants.

 

  d. Share-based compensation expense for employees and non-employees:

 

The Company recognized non-cash share-based compensation expenses for both employees and non-employees in the unaudited condensed consolidated statements of operations as follows (in thousands):

 

   

Nine Months Ended

September 30,

 
    2026     2025  
Cost of revenues   $ 10     $ 9  
Research and development, net     104       105  
Sales and marketing     99       203  
General and administrative     329       259  
Total   $ 542     $ 576  

 

  e. Warrants and Pre-Funded Warrants to purchase ordinary shares:

 

The following table summarizes information about warrants outstanding and exercisable that were classified as equity as of September 30, 2026:

 

Issuance date  

Warrants

outstanding

   

Exercise price

per warrant

   

Warrants

outstanding

and

exercisable

   

Contractual 

term 

    (number)           (number)      
September 29, 2021 (1)     95,314     $ 168.00       95,314     March 29, 2027
January 8, 2025 (2)     151,514     $ 33.00       151,514     January 10, 2028
January 8, 2025 (3)     9,088     $ 41.25       9,088     January 10, 2028
June 26, 2025 (4)     333,328     $ 7.8       333,328     June 26, 2030
June 26, 2025 (5)     20,000     $ 9.75       20,000     June 26, 2030
March 25, 2026 (6)     3,148,147     $ 5.40       3,148,147     March 25, 2031
March 25, 2026 (7)     1,006,113     $ 0.0001       1,006,113     No expiration
      4,763,504               4,763,504    

 

  (1) Represents warrants issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in September 2021.

 

  (2) Represents warrants issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in January 2025.

 

  (3) Represents warrants issued to the placement agent as compensation for its role in the Company’s January 2025 registered direct offering.

 

  (4) Represents warrants issued to certain institutional investors in connection with the Company’s public offering of ordinary shares in June 2025.

 

  (5) Represents warrants issued to the placement agent as compensation for its role in the Company’s public offering of ordinary shares in June 2025.

 

  (6) Represents warrants issued in connection with the Company’s March 2026 acquisition of Oratech and the related financing.

 

  (7) Represents pre-funded warrants issued as part of the consideration for the Company’s acquisition of Oratech in March 2026.

 

  f. Equity raise:

 

On January 7, 2025, the Company entered into a securities purchase agreement with certain institutional investors for the issuance and sale of 151,515 ordinary shares and warrants to purchase up to an aggregate of 151,514 ordinary shares at an exercise price of $33 per share. Each ordinary share was sold at an offering price of $33.00. The warrants became exercisable upon issuance and expire three years after the issuance date. The offering closed on January 8, 2025. In addition, the Company issued warrants to purchase up to 9,088 ordinary shares, with an exercise price of $41.25 per share, exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending three years from the date of issuance, to certain representatives of H.C. Wainwright & Co., LLC (“HCW”) as compensation for its role as the placement agent in the January 2025 private placement offering.

 

On March 7, 2025, the Company entered into an At-the-Market (“ATM”) Offering Agreement with HCW, pursuant to which the Company may, from time to time, offer and sell its ordinary shares through HCW acting as the Company’s sales agent.

 

During the three and nine months ended September 30, 2025, the Company sold 95,552 and 175,895 shares, respectively, of its ordinary shares under the ATM program at an average price of $7.20 and $11.04 per share, respectively, generating gross proceeds of approximately $0.7 million and $1.9 million. For the nine months ended September 30, 2025, the Company paid aggregate fees and commissions of $0.1 million to HCW and incurred other offering expenses of approximately $0.2 million, resulting in net proceeds of approximately $1.6 million. The Company’s ATM program expired on November 16, 2025, and no shares were issued under the program during the three and nine months ended September 30, 2026.

 

On June 25, 2025, the Company entered into a securities purchase agreement with certain institutional investors for the issuance and sale of 333,333 ordinary shares and warrants to purchase up to an aggregate of 333,328 ordinary shares at an exercise price of $7.8 per share. Each ordinary share was sold at a combined offering price of $7.80 together with a warrant to purchase one ordinary share. The warrants became exercisable upon issuance and expire five years after the issuance date. The offering closed on June 26, 2025.

 

Additionally, the Company issued warrants to purchase up to 20,000 ordinary shares, with an exercise price of $9.75 per share, which became exercisable upon issuance and expire five years after the issuance date, to certain representatives of HCW as compensation for its role as the placement agent in the June 2025 public offering.

 

The warrants issued in the January 2025 private placement and the June 2025 public offering are considered freestanding instruments. As the warrants are indexed to the Company’s ordinary shares and meet the criteria for equity classification, they are recorded in shareholders’ equity on the Company’s condensed consolidated balance sheets.